182 related articles for article (PubMed ID: 37706355)
1. Treg-targeted IL-2/anti-IL-2 complex controls graft-
Thiolat A; Pilon C; Caudana P; Moatti A; To NH; Sedlik C; Leclerc M; Maury S; Piaggio E; Cohen JL
Haematologica; 2024 Jan; 109(1):129-142. PubMed ID: 37706355
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
4. Modeling the interaction between donor-derived regulatory T cells and effector T cells early after allogeneic hematopoietic stem cell transplantation.
Nishiyama N; Ruoff P; Jimenez JC; Miwakeichi F; Nishiyama Y; Yata T
Biosystems; 2023 May; 227-228():104889. PubMed ID: 37019377
[TBL] [Abstract][Full Text] [Related]
5. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
Kennedy-Nasser AA; Ku S; Castillo-Caro P; Hazrat Y; Wu MF; Liu H; Melenhorst J; Barrett AJ; Ito S; Foster A; Savoldo B; Yvon E; Carrum G; Ramos CA; Krance RA; Leung K; Heslop HE; Brenner MK; Bollard CM
Clin Cancer Res; 2014 Apr; 20(8):2215-25. PubMed ID: 24573552
[TBL] [Abstract][Full Text] [Related]
6. Emerging translational strategies and challenges for enhancing regulatory T cell therapy for graft-versus-host disease.
Hippen KL; Hefazi M; Larson JH; Blazar BR
Front Immunol; 2022; 13():926550. PubMed ID: 35967386
[TBL] [Abstract][Full Text] [Related]
7. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
8. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
9. TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation.
Moatti A; Debesset A; Pilon C; Beldi-Ferchiou A; Leclerc M; Redjoul R; Charlotte F; To NH; Bak A; Belkacemi Y; Salomon BL; Issa F; Michonneau D; Maury S; Cohen JL; Thiolat A
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387779
[TBL] [Abstract][Full Text] [Related]
10. Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo.
Ramos TL; Bolivar-Wagers S; Jin S; Thangavelu G; Simonetta F; Lin PY; Hirai T; Saha A; Koehn B; Su LL; Picton LK; Baker J; Lohmeyer JK; Riddle M; Eide C; Tolar J; Panoskaltsis-Mortari A; Wagner JE; Garcia KC; Negrin RS; Blazar BR
Blood; 2023 Mar; 141(11):1337-1352. PubMed ID: 36564052
[TBL] [Abstract][Full Text] [Related]
11. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
12. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.
Meguri Y; Asano T; Yoshioka T; Iwamoto M; Ikegawa S; Sugiura H; Kishi Y; Nakamura M; Sando Y; Kondo T; Sumii Y; Maeda Y; Matsuoka KI
Front Immunol; 2022; 13():891925. PubMed ID: 35983059
[TBL] [Abstract][Full Text] [Related]
13. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
Yang K; Fan ZP; Liu QF; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
[TBL] [Abstract][Full Text] [Related]
14. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.
Xie Y; Wu M; Song R; Ma J; Shi Y; Qin W; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):781-91. PubMed ID: 19727527
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T Cell Amelioration of Graft-versus-Host Disease following Allogeneic/Xenogeneic Hematopoietic Stem Cell Transplantation Using Mobilized Mouse and Human Peripheral Blood Donors.
Barreras H; Copsel SN; Bader CS; Ding Y; Wolf D; Cash C; Stacey CJ; Benjamin C; Seavey MM; Wolf J; Jasuja RR; Pfeiffer B; Hill GR; Komanduri KV; Jurecic R; Malek TR; Levy RB
Transplant Cell Ther; 2023 May; 29(5):341.e1-341.e9. PubMed ID: 36804930
[TBL] [Abstract][Full Text] [Related]
16. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation.
Betts BC; Pidala J; Kim J; Mishra A; Nishihori T; Perez L; Ochoa-Bayona JL; Khimani F; Walton K; Bookout R; Nieder M; Khaira DK; Davila M; Alsina M; Field T; Ayala E; Locke FL; Riches M; Kharfan-Dabaja M; Fernandez H; Anasetti C
Haematologica; 2017 May; 102(5):948-957. PubMed ID: 28104702
[TBL] [Abstract][Full Text] [Related]
17. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
18. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
19. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.
Wang XN; Haniffa MA; Holtick U; Collin MP; Jackson G; Hilkens CM; Holler E; Edinger M; Hoffmann P; Dickinson AM
Transplantation; 2009 Jul; 88(2):188-97. PubMed ID: 19623013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
